Information Provided By: 
Fly News Breaks for March 4, 2020
FATE
Mar 4, 2020 | 06:44 EDT
Citi analyst Yigal Nochomovitz raised the firm's price target on Fate Therapeutics to $41 from $26 and keeps a Buy rating on the shares. Fate remains the analyst's preferred cell therapy play. The company continues to rapidly progress its iPSC pipeline, Nochomovitz tells investors in a research note.
News For FATE From the Last 2 Days
FATE
Apr 18, 2024 | 17:52 EDT
Check out this evening's top movers from around Wall Street, compiled by The Fly. HIGHER AFTER EARNINGSMetropolitan... To see the rest of the story go to thefly.com. See Story Here
